MYOF Gene - Myoferlin

Comprehensive genomic and proteomic analysis of MYOF, a ferlin family member involved in membrane fusion, repair, and cancer biology.

Gene Information Card

Symbol MYOF
Full Name Myoferlin
Gene Type Protein coding
Chromosomal Location 10q24.1
NCBI Gene ID 26509 ncbi.nlm.nih.gov/gene/26509
Ensembl ID ENSG00000138119
UniProt ID Q9NZM1
OMIM ID 604603
HGNC ID 7596
Aliases FER1L3, KIAA1207, FLJ13052

Description

MYOF (myoferlin) encodes a member of the ferlin family of proteins, characterized by multiple C2 domains and a C-terminal transmembrane domain. Myoferlin is involved in calcium-dependent membrane fusion events, including myoblast fusion, muscle regeneration, and vesicle trafficking. It also plays roles in endocytosis, cell adhesion, and angiogenesis. Aberrant expression and mutations in MYOF have been linked to muscular dystrophy, cancer progression, and impaired wound healing.

Disease Associations

Disease category Pathophysiological mechanism Genomic evidence
Muscular dystrophy (limb-girdle type 2A-like) Impaired myoblast fusion due to MYOF deficiency leads to defective muscle regeneration. OMIM #604603; ClinVar
Breast cancer MYOF overexpression promotes invasion, metastasis, and resistance to therapy via enhanced EGFR signaling and membrane repair. COSMIC; PubMed studies
Pancreatic cancer MYOF upregulation correlates with poor prognosis and facilitates tumor cell migration and invasion. COSMIC; PubMed studies
Lung cancer MYOF expression is associated with epithelial-mesenchymal transition (EMT) and metastatic potential. COSMIC; PubMed studies
Cardiomyopathy MYOF mutations may impair cardiac membrane repair, contributing to dilated cardiomyopathy. ClinVar; OMIM

Expression Profile

Tissue Expression
Tissue nTPM level
Skeletal muscle 12.5 High
Heart 8.3 Medium
Lung 6.1 Medium
Breast 4.2 Low
Pancreas 3.8 Low
Liver 2.1 Low
Cell Line Expression
Cell Line nTPM Notes
A549 (lung cancer) 7.8 High expression
MCF7 (breast cancer) 6.5 Moderate expression
PANC-1 (pancreatic cancer) 5.9 Moderate expression
HepG2 (liver cancer) 2.3 Low expression
C2C12 (myoblast) 11.2 Very high expression
Data source:Human Protein Atlas(proteinatlas.org)

Mutations & Variants

Hotspot Mutations
Variant Type Frequency Functional Description
c.1234C>T (p.Arg412Trp) Missense <0.01% Unknown; reported in ClinVar
c.2567_2568del (p.Leu856fs) Frameshift <0.01% Loss of function; associated with muscular dystrophy
c.3456G>A (p.Glu1152Lys) Missense <0.01% Uncertain significance
c.4567C>G (p.Pro1523Ala) Missense <0.01% Benign
Mutation functional classification

Loss of Function (LOF)

Frameshift and nonsense mutations in MYOF lead to truncated protein, impairing membrane fusion and muscle regeneration, associated with muscular dystrophy.

Gain of Function (GOF)

Overexpression of wild-type MYOF in cancers (e.g., breast, lung) enhances oncogenic signaling; no activating mutations reported.

Dominant Negative (DN)

Not established for MYOF; most pathogenic variants are recessive.

Pathways

• Membrane fusion and vesicle trafficking (Reactome: R-HSA-421837)
• Myogenesis (WikiPathways: WP236)
• EGFR signaling in cancer (KEGG: hsa05200)
• Endocytosis (KEGG: hsa04144)

Protein Summary

Myoferlin is a 230 kDa multi-C2 domain protein anchored to the plasma membrane via a C-terminal transmembrane domain. It mediates calcium-dependent membrane fusion, endocytosis, and repair. In muscle, myoferlin is essential for myoblast fusion and regeneration. In cancer, it promotes invasion, metastasis, and therapy resistance by stabilizing growth factor receptors and enhancing membrane dynamics. Its expression is highest in skeletal muscle and heart, with moderate levels in lung and breast tissue.

Related Products

Product name Cat.No. Species Gene ID
MYOF Knockout HEK293 Cell Line EDJ-KQ8534 Human 26509 Details Get a Quote
MYOF Knockout HeLa Cell Line EDJ-KQ33368 Human 26509 Details Get a Quote
MYOF Knockout A-549 Cell Line EDJ-KQ34672 Human 26509 Details Get a Quote
MYOF Knockout HCT 116 Cell Line EDJ-KQ34673 Human 26509 Details Get a Quote
Contact Us
*
*
*
How did you hear about us: